G

Genovis AB
STO:GENO

Watchlist Manager
Genovis AB
STO:GENO
Watchlist
Price: 28.05 SEK 3.13% Market Closed
Market Cap: 1.8B SEK
Have any thoughts about
Genovis AB?
Write Note

Genovis AB
Cash from Financing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Genovis AB
Cash from Financing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
G
Genovis AB
STO:GENO
Cash from Financing Activities
-kr5.8m
CAGR 3-Years
1%
CAGR 5-Years
-30%
CAGR 10-Years
N/A
AddLife AB
STO:ALIF B
Cash from Financing Activities
-kr554m
CAGR 3-Years
-14%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
BICO Group AB
STO:BICO
Cash from Financing Activities
-kr102m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Biotage AB
STO:BIOT
Cash from Financing Activities
-kr154m
CAGR 3-Years
13%
CAGR 5-Years
-7%
CAGR 10-Years
-12%
MedCap AB (publ)
STO:MCAP
Cash from Financing Activities
-kr89.5m
CAGR 3-Years
-7%
CAGR 5-Years
-9%
CAGR 10-Years
N/A
M
Magle Chemoswed Holding AB
STO:MAGLE
Cash from Financing Activities
kr2.5m
CAGR 3-Years
-52%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Genovis AB
Glance View

Market Cap
1.8B SEK
Industry
Life Sciences Tools & Services

Genovis AB engages in the research and development of enzyme products. The company is headquartered in Lund, Skane. The company went IPO on 2005-11-11. The firm offers products within two product portfolios, namely protein portfolio and nano portfolio. The protein portfolio develops products within the areas of cancer, inflammatory and autoimmune diseases. The portfolio comprises FabRICATOR, a genetically modified enzyme the cleaves antibodies in two parts, and IgGZERO, a protein that specifically cleaves the sugar molecules that occur naturally on antibodies. The products within the nano portfolio are primarily directed at the preclinical market. The firm markets and sells its products through dealers and distributors in the European, North American and Asian continents. As of December 31, 2011, it operated a wholly owned subsidiary, Eijdo Research AB.

GENO Intrinsic Value
24.64 SEK
Overvaluation 12%
Intrinsic Value
Price
G

See Also

What is Genovis AB's Cash from Financing Activities?
Cash from Financing Activities
-5.8m SEK

Based on the financial report for Jun 30, 2024, Genovis AB's Cash from Financing Activities amounts to -5.8m SEK.

What is Genovis AB's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
-30%

Over the last year, the Cash from Financing Activities growth was -81%. The average annual Cash from Financing Activities growth rates for Genovis AB have been 1% over the past three years , -30% over the past five years .

Back to Top